Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialChiara Cremolini, Sara Lonardi, Fotios Loupakis et al.|The Lancet Oncology|2020Cited by 322
Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal CancerMarinde J. G. Bond, Johannes J.M. Kwakman, Maarten van Smeden et al.|JCO Clinical Cancer Informatics|2024Cited by 6